The Role of Dietary Fiber in Mitigating Sarcopenia Risk in Head and Neck Cancer

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Oklahoma

About this trial

Emerging data suggest consumption of dietary fiber before and during cancer treatment may improve prognosis for patients with head and neck cancer, in part via increased production of short chain fatty acids, systemic anti-inflammatory effects, and decreased risk of sarcopenia. Foods rich in dietary fiber are often low in calories and protein, thus are not typically targeted in current treatment paradigms that focus on countering the catabolic state associated with sarcopenia. This project entails an observational, mixed methods study to: observe dietary fiber intake in patients with head and neck cancer from time of diagnosis for six months; elucidate the relationship between dietary fiber intake, short chain fatty acids, inflammatory markers, and sarcopenia; and explore the feasibility of and patient perceptions regarding promoting dietary fiber as part of their treatment approaches.

Eligibility criteria

Qualifiers

≥18 years of age

Newly diagnosed with squamous cell carcinoma of the: paranasal sinuses, nasal cavity, oral cavity, tongue, larynx, pharynx [i.e., nasopharynx, oropharynx, hypopharynx]

Meeting at least 60% of baseline energy needs

Willingness to provide data prior to treatment

Disqualifiers

Previously diagnosed or positive screen for a GI-related condition or eating disorder

Able to complete bioelectrical impedance (stand unsupported, no pacemaker or limb amputation) and Timed Chair Stands

Currently pregnant, planning to become pregnant, or breastfeeding

Current or past 3-month antibiotic use

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

59 Participants
are grouped into 1 trial group

Sponsors and collaborators